Sickle Cell Disease Treatment Market 2019-2025
発行: Orion Market Research Pvt Ltd
Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report, by Type (Medication (Hydroxyurea, L-Glutamine Oral Powder, Crizanlizumab, Voxelotor, Pain-relieving Medication, and others), Blood Transfusions and Bone-Marrow Transplant), by Disease Type (Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta-Thalassemia, and Sickle Beta-Zero Thalassemia), and Forecast 2019-2025
The global sickle cell disease treatment market is estimated to grow significantly during the forecast period. The major factors encouraging market growth include includes growing innovation by the pharmaceutical companies and the support of governments of various countries. For instance, in November 2019, the US FDA announced the approval of Adakveo (Crizanlizumab-tmca) treatment with the aim to reduce the frequency of vaso-occlusive crisis in the sickle cell disease patients of age 16 year and above. In November 2019, FDA approved the use of Voxelotor (Oxbryta) for sickle cell disease treatment. Voxelotor is a polymerization inhibitor used to reduce the concentration of deoxygenated sickle hemoglobin helping in stopping the formation of polymer in red blood cells.
The growing number of sickle cell anemia disease owing to the increase in demand for sickle cell anemia treatment encouraging the sickle cell disease treatment market to grow. Sickle cell anemia is a disorder in which the red blood cell unable to transport a significant amount of oxygen to the organs. In this condition, the red blood cell becomes rigid, sticky and sickle in shape resulting in blockages of oxygen through red blood cells. The growing initiatives by the government toward sickle cell anemia treatment encouraging major companies in the innovation of multiple treatment options. This in turn supporting the growth of the market.
The global sickle cell disease treatmentmarket is segmented based on type and disease type. Based on drug type, the market is classified into medication, blood transfusions, and a bone-marrow transplant. Based on disease type, the market is classified into sickle cell anemia, sickle hemoglobin c disease, sickle beta-thalassemia and sickle beta-zero thalassemia.Geographically, the global sickle cell disease treatment market is classified into North America, Europe, Asia-Pacific and the Rest of the World.
The major players in the global sickle cell disease treatment market include Emmaus Life Science, Inc., Bristol-Myers Squibb Co., Pfizer, Inc., Global Blood Therapeutics, Inc., and Novartis AG. The strategies followed by the market players include mergers and acquisitions, partnerships and collaborations and geographical expansion to expand market share across the globe.For instance, in November 2016, Novartis AG announced its acquisition of Selexys Pharmaceuticals and the SelG1 antibody with the aim of reduced pain treatment for sickle cell disease patients in adults. This acquisition will strengthen Novartis's product portfolio of sickle cell disease treatment.
The market study of the global sickle cell disease treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary Sources Include:
The report is intended for drug manufacturers, suppliers and distributors, and government agenciesfor overall market analysis and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
The Report Covers: